Persius/hicric huggingface dataset:
The Living Guidelines: Patients with Wolff Parkinson White syndrome (WPW): Suggest Revisions to the CLASS I Guidelines

# Class I Guidelines
- Catheter ablation of the accessory pathway is recommended in symptomatic patients with AF who have WPW syndrome, particularly those with syncope due to rapid heart rate or those with a short bypass tract refractory period. (Level of Evidence: B) 
- Immediate direct-current cardioversion is recommended to prevent ventricular fibrillation in patients with a short anterograde bypass tract refractory period in whom AF occurs with a rapid ventricular response associated with hemodynamic instability. (Level of Evidence: B) 
- Intravenous procainamide or ibutilide is recommended to restore sinus rhythm in patients with WPW syndrome in whom AF occurs without hemodynamic instability in association with a wide QRS complex on the ECG (greater than or equal to 120-ms duration) or with a rapid pre-excited ventricular response. (Level of Evidence: C)
Guidelines for the management of aSAH (surgical and endovascular methods of treatment of ruptured cerebral aneurysms)

# 2012 AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage

## Surgical and Endovascular Methods of Treatment of Ruptured Cerebral Aneurysms: Recommendations
The Living Guidelines: Patients with postoperative atrial fibrillation: Suggest Revisions to the CLASS IIa Guidelines

# Class IIa Guidelines
- Preoperative administration of amiodarone] reduces the incidence of AF in patients undergoing cardiac surgery and represents appropriate prophylactic therapy for patients at high risk for po
- It is reasonable to restore sinus rhythm by pharmacological cardioversion with ibutilide or direct current cardioversion in patients who develop postoperative AF as advised for nonsurgical patients. (Level of Evidence: B) 
- It is reasonable to administer antiarrhythmic medications in an attempt to maintain sinus rhythm in patients with recurrent or refractory postoperative AF, as recommended for other patients who develop AF. (Level of Evidence: B) 
- It is reasonable to administer antithrombotic medication in patients who develop postoperative AF, as recommended for nonsurgical patients. (Level of Evidence: B)
The Living Guidelines: Pharmacological Cardioversion of Atrial Fibrillation: Polling Results for CLASS IIb Guidelines

# Class IIb Guidelines
1. Administration of quinidine or procainamide might be considered for pharmacological cardioversion of AF, but the usefulness of these agents is not well established. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIb Recommendation 1 for pharmacological cardioversion of atrial fibrillation should be:
The Living Guidelines: Pharmacological rate control during atrial fibrillation Polling Results for CLASS I Guidelines

# Class I Guidelines
1. Measurement of the heart rate at rest and control of the rate using pharmacological agents (either a beta blocker or non dihydropyridine calcium channel antagonist, in most cases) are recommended for patients with persistent or permanent AF. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 1 for pharmacological rate control during atrial fibrillation should be:
2. In the absence of pre-excitation, intravenous administration of beta blockers (esmolol, metoprolo], or propranolol) or non dihydropyridine calcium channel antagonists (verapamil, diltiazem) is recommended to slow the ventricular response to AF in the acute setting, exercising caution in patients with hypotension or heart failure. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 2 for pharmacological rate control during atrial fibrillation should be:
3. Intravenous administration of digoxin or amiodarone is recommended to control the heart rate in patients with AF and heart failure who do not have an accessory pathway. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 3 for pharmacological rate control during atrial fibrillation should be:
4. In patients who experience symptoms related to AF during activity, the adequacy of heart rate control should be assessed during exercise, adjusting pharmacological treatment as necessary to keep the rate in the physiological range. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 4 for pharmacological rate control during atrial fibrillation should be:
5. Digoxin is effective following oral administration to control the heart rate at rest in patients with AF and is indicated for patients with heart failure, LV dysfunction, or for sedentary individuals. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 5 for pharmacological rate control during atrial fibrillation should be:
The Living Guidelines: Patients with Wolff Parkinson White syndrome (WPW): Polling Results for CLASS III Guidelines

# Class III Guidelines
1. Intravenous administration of digitalis glycosides or non dihydropyridine calcium channel antagonists is not recommended in patients with WPW syndrome who have pre-excited ventricular activation during AF. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class III Recommendation 1 for patients with Wolff Parkinson White syndrome (WPW) should be:
The Living Guidelines: Patients with Wolff Parkinson White syndrome (WPW): Polling Results for CLASS IIa Guidelines

# Class IIa Guidelines
1. Intravenous flecainide or direct-current cardioversion is reasonable when very rapid ventricular rates occur in patients with AF involving conduction over an accessory pathway. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 1 for patients with Wolff Parkinson White syndrome (WPW) should be:
The Living Guidelines: Patients with Wolff Parkinson White syndrome (WPW): Polling Results for CLASS IIb Guidelines

# Class IIb Guidelines
1. It may be reasonable to administer intravenous quinidine, procainamide, disopyramide, ibutilide, or amiodarone to hemodynamically stable patients with AF involving conduction over an accessory pathway. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIb Recommendation 1 for patients with Wolff Parkinson White syndrome (WPW) should be:
The Living Guidelines: Patients with postoperative atrial fibrillation: Suggest Revisions to the CLASS I Guidelines

# Class I Guidelines
- Unless contraindicated, treatment with an oral beta blocker to prevent postoperative AF is recommended for patients undergoing cardiac surgery. (Level of Evidence: A) 
- Administration of AV nodal blocking agents is recommended to achieve rate control in patients who develop postoperative AF. (Level of Evidence: B)
The Living Guidelines: Pharmacological Cardioversion of Atrial Fibrillation: Polling Results for CLASS I Guidelines

# Class I Guidelines
1. Administration of flecainide, dofetilide, propafenone, or ibutilide is recommended for pharmacological cardioversion of AF. (Level of Evidence: A) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 1 for pharmacological cardioversion of atrial fibrillation should be:
The Living Guidelines: Patients with Wolff Parkinson White syndrome (WPW): Polling Results for CLASS I Guidelines

# Class I Guidelines
1. Catheter ablation of the accessory pathway is recommended in symptomatic patients with AF who have WPW syndrome, particularly those with syncope due to rapid heart rate or those with a short bypass tract refractory period. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 1 for patients with Wolff Parkinson White syndrome (WPW) should be:
2. Immediate direct-current cardioversion is recommended to prevent ventricular fibrillation in patients with a short anterograde bypass tract refractory period in whom AF occurs with a rapid ventricular response associated with hemodynamic instability. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 2 for patients with Wolff Parkinson White syndrome (WPW)should be:
3. Intravenous procainamide or ibutilide is recommended to restore sinus rhythm in patients with WPW syndrome in whom AF occurs without hemodynamic instability in association with a wide QRS complex on the ECG (greater than or equal to 120-ms duration) or with a rapid pre-excited ventricular response. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 3 for patients with Wolff Parkinson White syndrome (WPW) should be:
The Living Guidelines: Patients with postoperative atrial fibrillation: Polling Results for CLASS IIa Guidelines

# Class IIa Guidelines
1. Preoperative administration of amiodarone reduces the incidence of AF in patients undergoing cardiac surgery and represents appropriate prophylactic therapy for patients at high risk for po
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 1 for patients with postoperative atrial fibrillation should be:
2. It is reasonable to restore sinus rhythm by pharmacological cardioversion with ibutilide or direct current cardioversion in patients who develop postoperative AF as advised for nonsurgical patients. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 2 for patients with postoperative atrial fibrillation should be:
3. It is reasonable to administer antiarrhythmic medications in an attempt to maintain sinus rhythm in patients with recurrent or refractory postoperative AF, as recommended for other patients who develop AF. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 3 for patients with postoperative atrial fibrillation should be:
4. It is reasonable to administer antithrombotic medication in patients who develop postoperative AF, as recommended for nonsurgical patients. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 4 for patients with postoperative atrial fibrillation should be:
The Living Guidelines: Patients with postoperative atrial fibrillation: Polling Results for CLASS IIb Guidelines

# Class IIb Guidelines
1. Prophylactic administration of sotalol may be considered for patients at risk of developing AF following cardiac surgery. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIb Recommendation 1 for patients with postoperative atrial fibrillation should be:
Class III recommendations in guidelines for cardiovascular medicine organized by year of guideline publication

# Overview
There are 584 class III recommendations in guidelines published by American cardiology societies. Class III recommendations may be classified either by guideline name/year of publication or by recommendation level of evidence.

# Organized by Year of Guideline Publication
The table shown below is a list of class III recommendations obtained from American guidelines for cardiovascular medicine. The list is organized by year of publication (from newest to oldest). Alternatively, to view the same list organized by guideline name/keyword, click here.
The Living Guidelines: Patients with postoperative atrial fibrillation: Polling Results for CLASS I Guidelines

# Class I Guidelines
1. Unless contraindicated, treatment with an oral beta blocker to prevent postoperative AF is recommended for patients undergoing cardiac surgery. (Level of Evidence: A) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 1 for patients with postoperative atrial fibrillation should be:
2. Administration of AV nodal blocking agents is recommended to achieve rate control in patients who develop postoperative AF. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 2 for patients with postoperative atrial fibrillation should be:
The Living Guidelines: Patients with acute myocardial infarction: Suggest Revisions to the CLASS I Guidelines

# Class I Guidelines
- Direct-current cardioversion is recommended for patients with severe hemodynamic compromise or intractable ischemia, or when adequate rate control cannot be achieved with pharmacological agents in patients with acute MI and AF. (Level of Evidence: C) 
- Intravenous administration of amiodarone is recommended to slow a rapid ventricular response to AF and improve LV function in patients with acute MI. (Level of Evidence: C) 
- Intravenous beta blockers and non dihydropyridine calcium channel antagonists are recommended to slow a rapid ventricular response to AF in patients with acute MI who do not display clinical LV dysfunction, bronchospasm, or AV block. (Level of Evidence: C) 
- For patients with AF and acute MI, administration of unfractionated heparin by either continuous intravenous infusion or intermittent subcutaneous injection is recommended in a dose sufficient to prolong the activated partial thromboplastin time to 1.5 to 2.0 times the control value, unless contraindications to anticoagulation exist. (Level of Evidence: C)
Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents

# Overview
Children and adolescents with high-risk hyperlipidemia require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia, despite compliance with lifestyle recommendations.

# NCEP Recommendations for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents

## Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents  (DO NOT EDIT)

## Current Modifications of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents  (DO NOT EDIT)
The Living Guidelines: Patients with Pulmonary Hypertension: Suggest Revisions to the CLASS III Guidelines

# Class III Guidelines
- Theophylline and beta-adrenergic agonist agents are not recommended in patients with bronchospastic lung disease who develop AF. (Level of Evidence: C) 
- Beta blockers, sotalol, propafenone, and adenosine are not recommended in patients with obstructive lung disease who develop AF. (Level of Evidence: C)
The Living Guidelines: Patients with acute myocardial infarction: Polling Results for CLASS III Guidelines

# Class III Guidelines
1. The administration of class IC antiarrhythmic drugs is not recommended in patients with AF in the setting of acute MI. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class III Recommendation 1 for patients with acute myocardial infarction should be:
The Living Guidelines: Patients with acute myocardial infarction: Polling Results for CLASS IIa Guidelines

# Class IIa Guidelines
1. Intravenous administration of digitalis is reasonable to slow a rapid ventricular response and improve LV function in patients with acute MI and AF associated with severe LV dysfunction and heart failure. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 1 for patients with acute myocardial infarction should be:
The Living Guidelines: Patients with hypertrophic cardiomyopathy: Polling Results for CLASS IIa Guidelines

# Class IIa Guidelines
1. Antiarrhythmic medications can be useful to prevent recurrent AF in patients with hypertrophic cardiomyopathy. Available data are insufficient to recommend one agent over another in this situation, but (a) disopyramide combined with a beta blocker or non dihydropyridine calcium channel antagonist or (b) amiodarone alone is generally preferred. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class IIa Recommendation 1 for patients with hypertrophic cardiomyopathy should be:
Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes
Synonyms and keywords: Apo A-1 Milano, ETC 216, MDCO 216

# Official Title
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

# Objective
- To study the effects of intravenous recombinant Apo A-1 Milano/phospholipid complexes (ETC-216) on arterial plaque burden in patients with acute coronary syndromes (ACS).

# Timeline

# Study Description

# Methods
- A 5 week, randomized, double-blinded, multicenter, parallel-treatment randomized control trial
- Patients enrolled: 123 patients
- Patients completed the protocol: 47 patients
IVUS was done at baseline.  Intravenous infusion took place weekly for 5 consecutive weeks.  Two weeks after infusion, IVUS was repeated for comparison.

# Eligibility Criteria

## Inclusion Criteria
- Age: 30-75 years
- Angiography performed within 14 days following ACS event.
- At least 20% luminal diameter stenosis by visual estimated required
- Intravascular ultrasound (IVUS) done within 14 days of ACS event.
- No more than 50% luminal narrowing in a segment that is at least 30 mm in length.
- No previous percutaneous coronary intervention (PCI)
- Other anti-lipidemic drugs permitted during the study as long as no introduction or new medication or change in dosage occurs within 6 weeks of study start or end date.

## Outcomes

### Primary Outcome
Change in percent atheroma volume as measured by IVUS

### Secondary Outcomes
Assessment of adverse events, quantitative angiographic changes, change in average maximal thickness or in total volume of atheroma,or atheroma volume change in most and least severely diseases 10-mm-long segments.

# Publications

## Results
- 10 patients were discontinued, while another 3 elected to discontinue
- 2 patients were withdrawn for adverse events
- 5 had IVUS that could not be analyzed
There was a significant difference in atheroma volume, mean change in total atheroma volume and thickness in the ETC-216 groups (combined) showing a 3.17% difference (p=0.02, p<0.001, p<0.001  respectively). This statistical significance was not seen in patients on placebo. Most regression using ETC-216 was seen in subsegments of 10 mm long that are severely diseased, in comparison to those with only mild disease (p<0.001).
However, luminal diameter on angiography was not different when comparing follow-up to baseline or when comparing ETC-216 vs. placebo.
Adverse events included mainly minor gastrointestinal events, headaches,arthralgias, and edema that were found in all 3 groups.
Two important adverse events that required withdrawal were:
- 1 patient with elevated liver function tests 3 times the upper normal limit with nausea vomiting, and cholelithiasis.
- 1 patient with chills, rigors, rash, nausea, vomiting, and diaphoresis that occurred during infusion.

## Conclusion
Although Apo A-1 Milano infusions resulted in a decrease in plaque burden, further study is required to assess efficacy, safety and cost-effectiveness.
ST Elevation Myocardial Infarction Inhibition of the Renin-Angiotensin-Aldosterone System as Initial Care

# Overview

# Guidelines (Do not edit) 

# Sources
- The 2004 ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction 
- The 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction
The Living Guidelines: Patients with Pulmonary Hypertension: Suggest Revisions to the CLASS I Guidelines

# Class I Guidelines
- Correction of hypoxemia and acidosis is the recommended primary therapeutic measure for patients who develop AF during an acute pulmonary illness or exacerbation of chronic pulmonary disease. (Level of Evidence: C) 
- A non dihydropyridine calcium channel antagonist (diltiazem or verapamil) is recommended to control the ventricular rate in patients with obstructive pulmonary disease who develop AF. (Level of Evidence: C) 
- Direct-current cardioversion should be attempted in patients with pulmonary disease who become hemodynamically unstable as a consequence of AF. (Level of Evidence: C)
The Living Guidelines: Patients with acute myocardial infarction: Polling Results for CLASS I Guidelines

# Class I Guidelines
1. Direct-current cardioversion is recommended for patients with severe hemodynamic compromise or intractable ischemia, or when adequate rate control cannot be achieved with pharmacological agents in patients with acute MI and AF. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 1 for patients with acute myocardial infarction should be:
2. Intravenous administration of amiodarone is recommended to slow a rapid ventricular response to AF and improve LV function in patients with acute MI. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 2 for patients with acute myocardial infarction should be:
3. Intravenous beta blockers and non dihydropyridine calcium channel antagonists are recommended to slow a rapid ventricular response to AF in patients with acute MI who do not display clinical LV dysfunction, bronchospasm, or AV block. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 3 for patients with acute myocardial infarction should be:
4. For patients with AF and acute MI, administration of unfractionated heparin by either continuous intravenous infusion or intermittent subcutaneous injection is recommended in a dose sufficient to prolong the activated partial thromboplastin time to 1.5 to 2.0 times the control value, unless contraindications to anticoagulation exist. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 4 for patients with acute myocardial infarction should be:
The Living Guidelines: Patients with hypertrophic cardiomyopathy: Polling Results for CLASS I Guidelines

# Class I Guidelines
1. Oral anticoagulation (INR 2.0 to 3.0) is recommended in patients with hypertrophic cardiomyopathy who develop AF, as for other patients at high risk of thromboembolism. (Level of Evidence: B) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class I Recommendation 1 for patients with hypertrophic cardiomyopathy should be:
The Living Guidelines: Patients with Pulmonary Hypertension: Polling Results for CLASS III Guidelines

# Class III Guidelines
1. Theophylline and beta-adrenergic agonist agents are not recommended in patients with bronchospastic lung disease who develop AF. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class III Recommendation 1 for patients with pulmonary hypertension should be:
2. Beta blockers (sotalol, propafenone) and adenosine are not recommended in patients with obstructive lung disease who develop AF. (Level of Evidence: C) 
ACC / AHA 2008 guidelines for diagnosis and management of atrial fibrillation: Class III Recommendation 2 for patients with pulmonary hypertension should be: